{"schema_version":"secwatch.filing_event.v1","accession":"0001370053-25-000063","form_type":"8-K","ticker":"ANAB","cik":"0001370053","company_name":"ANAPTYSBIO, INC","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.828606+00:00","generated_at":"2026-05-17T19:01:47.736511+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AnaptysBio Q2 net loss narrows to $38.6M; rosnilimab Phase 2b RA data positive","bullets":["Net loss $38.6M ($1.34/sh) vs $46.7M ($1.71) YoY; collaboration revenue $22.3M, up from $11.0M.","Cash & investments $293.7M as of June 30, 2025; cash runway through year-end 2027 reiterated.","Rosnilimab RA Phase 2b shows JAK-like efficacy, durable off-drug response; UC Phase 2 enrollment complete, top-line Q4 2025.","ANB033 (CD122 antagonist) to begin Phase 1b in celiac disease by Q4 2025; R&D event planned.","Anticipate $75M GSK milestone in 2025 once Jemperli achieves $1B annual net sales."],"urls":{"canonical":"https://secwatch.observer/filing/0001370053-25-000063","json":"https://secwatch.observer/filing/0001370053-25-000063.json","markdown":"https://secwatch.observer/filing/0001370053-25-000063.md","text":"https://secwatch.observer/filing/0001370053-25-000063.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1370053/000137005325000063/0001370053-25-000063-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1370053/000137005325000063/anab-20250806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T19:01:47.736511+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}